- Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA® or OPDIVO® can result in improved patient outcomes - MDSCs – Myeloid Derived Suppressor Cells in the tumor ...
Preclinical data demonstrate enhanced efficacy of PLT012 in pMMR colorectal cancer models - Findings position CD36 as a promising metabolic checkpoint target in an underserved patient population DOVER ...
The FDA has approved a drug for patients who are 12 and older with classical Hodgkin lymphoma based on the results of a ...
Potential breakthrough therapeutic targets $50B+ global immunotherapy market1CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, ...
DUBLIN--(BUSINESS WIRE)--The "Oncolytic Virus Immunotherapy - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Oncolytic Virus Immunotherapy ...
Combination immune checkpoint inhibitor therapy (ICI) with ipilimumab (anti–cytotoxic T-lymphocyte–associated protein 4) + nivolumab (anti–PD-1) in untreated, metastatic melanoma has achieved a ...
We conducted a prospective study of patients with solid tumors who received pembrolizumab or atezolizumab at the National Institute of Oncology, Rabat from July 2018 to December 2023. We identified ...
Frontline gastric/GE junction cancer care now pairs chemo with checkpoint inhibitors for PD-L1 CPS≥1, improving survival and ...
Treatment paradigms remain unclear for immune-related adverse events associated with cancer checkpoint inhibitor therapies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results